论文部分内容阅读
目的：探讨低分子右旋糖酐加速尿对治疗原发性肾病综合征的影响。方法：３０例原发性肾病综合征，随机分为治疗组（Ａ组）１６例静脉缓慢输注低分子右旋糖酐加速尿；对照组（Ｂ组）１４例输注人体白蛋白或血浆，然后给予速尿治疗，两组的强的松治疗方案相同，疗程１２周。结果：Ａ组总缓解率为９３．７５％，Ｂ组总缓解率为９２．８６％，无显著性差异（Ｐ＞０．０５）；而Ａ组达到完全缓解所需２２．１０±１１．３０天，与Ｂ组达到完全缓解所需４８．６６±２１．１１天比较有非常显著性差异（Ｐ＜０．０１），治疗期间Ａ组浮肿消退较Ｂ组好，无严重不良反应。结论：低分子右旋糖酐加速尿缓慢静脉注入不影响强的松疗效，利尿消肿好，副作用少。
Objective: To investigate the effect of low molecular dextran accelerated urine on the treatment of primary nephrotic syndrome. Methods: Thirty patients with primary nephrotic syndrome were randomly divided into treatment group (group A) with intravenous infusion of low molecular weight dextran and slow intravenous infusion of 16 patients. In control group (group B), 14 patients received human albumin or plasma infusion, Furosemide treatment, the two groups of prednisone treatment of the same course of 12 weeks. Results: The total remission rate in group A was 93.75%, and the total remission rate in group B was 92.86% (P> 0.05), while that in group A was 22.10 ± 11. 30 days, compared with 48.66 ± 21.11 days required for complete remission in group B (P <0.01). The edema of group A was better than that of group B during treatment, and no serious side effects occurred. Conclusion: Slow dextran injection of slow intravenous urea does not affect the efficacy of prednisone, diuretic swelling is good, less side effects.